中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
28期
40-42
,共3页
静脉注射%口服铁剂%治疗%肾性贫血
靜脈註射%口服鐵劑%治療%腎性貧血
정맥주사%구복철제%치료%신성빈혈
Intravenous injection%Oral ferralia%Treatment%Renal anemia
目的 探讨静脉注射和口服铁剂治疗肾性贫血的效果. 方法 该院随机选取了2013年10月—2014年10月期间来治疗的60例肾性贫血患者作为研究对象,利用计算机软件把60例患者随机分成两组,观察组和对照组,每组30例患者. 给予对照组口服铁剂治疗,观察组静脉注射治疗,比较观察两组治疗疗效. 结果 观察组治疗前的铁蛋白检测数据为(94.58± 12.86)ng/mL,对照组为(95.01±15.62)ng/mL,观察组治疗后的铁蛋白检测数据为(126.26±6.85) ng/mL,对照组治疗后为(102.52±8.92) ng/mL;观察组治疗后的Hb、Hct改善情况明显优于对照组;两组差异有统计学意义(P<0.05).两组患者治疗中的不良反应差异无统计学意义(P>0.05). 结论 对肾性贫血患者使用静脉方式进行治疗安全、有效,可将患者临床病症有效改善,可推广治疗.
目的 探討靜脈註射和口服鐵劑治療腎性貧血的效果. 方法 該院隨機選取瞭2013年10月—2014年10月期間來治療的60例腎性貧血患者作為研究對象,利用計算機軟件把60例患者隨機分成兩組,觀察組和對照組,每組30例患者. 給予對照組口服鐵劑治療,觀察組靜脈註射治療,比較觀察兩組治療療效. 結果 觀察組治療前的鐵蛋白檢測數據為(94.58± 12.86)ng/mL,對照組為(95.01±15.62)ng/mL,觀察組治療後的鐵蛋白檢測數據為(126.26±6.85) ng/mL,對照組治療後為(102.52±8.92) ng/mL;觀察組治療後的Hb、Hct改善情況明顯優于對照組;兩組差異有統計學意義(P<0.05).兩組患者治療中的不良反應差異無統計學意義(P>0.05). 結論 對腎性貧血患者使用靜脈方式進行治療安全、有效,可將患者臨床病癥有效改善,可推廣治療.
목적 탐토정맥주사화구복철제치료신성빈혈적효과. 방법 해원수궤선취료2013년10월—2014년10월기간래치료적60례신성빈혈환자작위연구대상,이용계산궤연건파60례환자수궤분성량조,관찰조화대조조,매조30례환자. 급여대조조구복철제치료,관찰조정맥주사치료,비교관찰량조치료료효. 결과 관찰조치료전적철단백검측수거위(94.58± 12.86)ng/mL,대조조위(95.01±15.62)ng/mL,관찰조치료후적철단백검측수거위(126.26±6.85) ng/mL,대조조치료후위(102.52±8.92) ng/mL;관찰조치료후적Hb、Hct개선정황명현우우대조조;량조차이유통계학의의(P<0.05).량조환자치료중적불량반응차이무통계학의의(P>0.05). 결론 대신성빈혈환자사용정맥방식진행치료안전、유효,가장환자림상병증유효개선,가추엄치료.
Objective To investigate the effect of intravenous injection of ferralia and oral oral ferralia in the treatment of renal anemia. Methods Sixty patients with renal anemia treated in our hospital from October 2013 to October 2014 were selected as the subjects and randomly divided into two groups, the observation group and the control group with 30 cases in each by computer software. Patients in the control group were treated by oral ferralia and those in the observation group were treated by intravenous injection of ferralia. And the efficacy of the two groups was observed and compared. Results Before treatment, the ferritin level was (94.58 ± 12.86) ng/mL in the observation group, and that was (95.01±15.62)ng/mL in the control group. After treatment, the ferritin level was (126.26±6.85) ng/mL in the observation group, and that was (102.52±8.92) ng/mL in the control group. The improvement of Hb and Hct level after treatment was much better in the observation group than that in the control group with statistically signif-icant difference(P<0.05). The difference in the incidence of adverse reactions during the treatment between the two groups was not statistically significant(P>0.05). Conclusion For patients with renal anemia, intravenous injection of ferralia is safe, effective, which can effectively improve the clinical symptoms, so it is can be promoted.
